Cite
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
MLA
Olivier, Arnaud, et al. “Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction: Potential Effect Modification by Abdominal Obesity. Insight from the EMPHASIS-HF Trial.” European Journal of Heart Failure, vol. 19, no. 9, Sept. 2017, pp. 1186–97. EBSCOhost, https://doi.org/10.1002/ejhf.792.
APA
Olivier, A., Pitt, B., Girerd, N., Lamiral, Z., Machu, J.-L., McMurray, J. J. V., Swedberg, K., van Veldhuisen, D. J., Collier, T. J., Pocock, S. J., Rossignol, P., Zannad, F., & Pizard, A. (2017). Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. European Journal of Heart Failure, 19(9), 1186–1197. https://doi.org/10.1002/ejhf.792
Chicago
Olivier, Arnaud, Bertram Pitt, Nicolas Girerd, Zohra Lamiral, Jean-Loup Machu, John J.V. McMurray, Karl Swedberg, et al. 2017. “Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction: Potential Effect Modification by Abdominal Obesity. Insight from the EMPHASIS-HF Trial.” European Journal of Heart Failure 19 (9): 1186–97. doi:10.1002/ejhf.792.